-transparent.png){kind=logo}
The purpose of this cross-sectional study was to evaluate the effects of human parathyroid hormone(1-84) (hPTH) followed by maintenance treatment with 17beta-estradiol (E(2)), risedronate (Ris), or a reduced dose of hPTH (LowPTH) on cortical bone in the ovariectomized (ovx) rat. Eight groups of ovx and one group of intact female rats (3.5 months) were left untreated for 11 weeks. For the following 12 weeks, four groups received subcutaneous injections of hPTH (75 microg/kg per day on 3 days/week) and four groups received vehicle. Treatments were then changed to E(2) (10 microg/kg per day on 2 days/week), Ris (3 microg/kg per day on 3 days/week), LowPTH (25 microg/kg per day on 3 days/week), or vehicle. Bone tissue was collected at weeks -11 (baseline), 0 (ovx effect), 12 (hPTH effect), 24, 36, and 48 (maintenance effect). Bone mineral density (BMD) and bone mineral content (BMC) of the diaphyseal femur and total cross-sectional area (Tt.Ar), marrow area (Ma.Ar), cortical area (Ct.Ar), and periosteal and endocortical bone formation of the tibia were measured. Ovariectomy resulted in lower BMD (weeks 0-48), unaffected BMC, and greater Tt.Ar (weeks 12 and 36), Ma.Ar (week 48), and Ct.Ar (weeks 0 and 12) compared with intact rats. Endocortical and periosteal bone formation were greater in the ovx than in the intact rats up to 23 weeks postovariectomy. Treatment of ovx rats with hPTH for 12 weeks resulted in greater cortical BMD, BMC, and endocortical bone formation than in intact or ovx controls. In ovx rats pretreated with hPTH and then treated with Ris for 36 weeks, BMD and BMC were greater and Ma.Ar was smaller than in ovx controls. In ovx rats pretreated with hPTH and then treated with LowPTH, BMD, BMC, Ct.Ar, and endocortical bone formation were greater and Ma.Ar was smaller than in ovx controls. Treatment of hPTH-pretreated rats with E(2) for 36 weeks did not affect cortical BMD, BMC, and Ct.Ar, although periosteal bone formation was lower in the E(2) group compared with the ovx group. Thus, in ovariectomized rats, cortical bone gained by 12 weeks of hPTH treatment was maintained for up to 36 weeks by treatment with risedronate or low-dose hPTH, but not with 17beta-estradiol.
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
June 2004,
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
January 2001,
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
October 2006,
Calcified tissue international,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
January 1994,
Bone,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
September 1993,
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
June 1988,
Endocrinology,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
January 2020,
Medicina,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
October 1997,
Endocrinology,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
June 2002,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
E Samnegård, and
U T Iwaniec, and
D M Cullen, and
D B Kimmel, and
R R Recker
April 2001,
Bone,
